Pharmsintez's RAS loss for 6 months of 2024 amounted to ₽74.31 million, down 46.2% from ₽138 million in the previous year. Revenue declined 19.8% to ₽102.24 million from ₽127.53 million a year earlier.

Pharmsintez's RAS loss for 3 months of 2024 amounted to ₽241.57 million, down 8.7% from ₽264.54 million in the previous year. Revenue declined 7.9% to ₽284.64 million from ₽309.09 million a year earlier.

Pharmsintez's RAS loss for 2023 amounted to ₽241.57 million, down 8.7% from ₽264.54 million in the previous year. Revenue declined 8% to ₽284.4 million from ₽309.09 million a year earlier.

Pharmsintez sold the Estonian plant Kevelt. The buyer was Dmitry Genkin, Chairman of the Board of Directors of the company. Transactions amounted to €224.8 thousand. At the same time, the parties entered into an option, according to which Pharmsintez has the right to buy back the shares within ten years. Companies also offset the counterclaims on the debt of...